Drug Trial Radar · NCT04561245
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Nov 10, 2020
Primary completion
Oct 29, 2021
Study completion Oct 29, 2021
Sponsor
- Lead sponsor
- Altimmune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects. The purpose of the study was to assess the safety and tolerability in healthy overweight and obese volunteers administered single or multiple repeated doses of ALT-801 (pemvidutide).
Conditions
- Obesity
- Nonalcoholic Steatohepatitis
Interventions
ALT-801Drug
Injected subcutaneously (SC)
PlaceboOther
Injected subcutaneously (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)Time frame: Part 1 SAD Cohorts: up to Day 26; Part 2 MAD Cohorts: up to Day 42
- Pharmacokinetic (PK): Maximum observed concentration (Cmax) of ALT-801Time frame: Baseline, Day 26
- Pharmacokinetic (PK): Area Under the Concentration (AUC) vs Time Curve of ALT-801Time frame: Baseline to Day 26
- Change in body weightTime frame: Baseline to Week 6
- Pharmacodynamic (PD): Change from baseline in magnetic resonance derived proton density fat fraction (MRI-PDFF)Time frame: Baseline to Week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Networks
Herston, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.